CHO cell expression, long-term stability, and primate pharmacokinetics and brain uptake of an IgG-paroxonase-1 fusion protein

Biotechnology and Bioengineering

Volumn 108, Issue 1, 2011, Pages 186-196

  Boado, Ruben J ^a,b   Hui, Eric Ka Wai ^a   Lu, Jeff Zhiqiang ^a   Pardridge, William M ^b  

^a ArmaGen Technologies Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood brain barrier; Delivery systems; Monoclonal antibody; Organophosphate; Paroxonase 1

Indexed keywords

ANION EXCHANGE CHROMATOGRAPHY; BLOOD-BRAIN BARRIER; BRAIN UPTAKE; CARBOXYL TERMINUS; CENTRAL NERVOUS SYSTEMS; CHINESE HAMSTER OVARY CELLS; CHO CELL; DELIVERY SYSTEMS; FUSION PROTEINS; HEAVY CHAIN; HOST CELLS; INSULIN RECEPTORS; LIQUID FORMULATIONS; LONG TERM STABILITY; MONOCLONAL ANTIBODIES (MAB); ORGANOPHOSPHATE; PAROXONASE-1; PROTEIN A; RHESUS MONKEY;

AFFINITY CHROMATOGRAPHY; AMINO ACIDS; BLOOD; MERGERS AND ACQUISITIONS; MONOCLONAL ANTIBODIES; PHARMACOKINETICS; SURFACE PLASMON RESONANCE;

PROTEINS;

ARYLDIALKYLPHOSPHATASE 1; IMMUNOGLOBULIN G; INSULIN RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN A;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANION EXCHANGE CHROMATOGRAPHY; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; CHO CELL; CONTROLLED STUDY; DRUG IMPURITY; DRUG MEGADOSE; DRUG POTENCY; DRUG PURITY; DRUG STABILITY; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC TRANSFECTION; GRAY MATTER; LOW DRUG DOSE; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PROTEIN PURIFICATION; RHESUS MONKEY; SKELETAL MUSCLE; WESTERN BLOTTING; WHITE MATTER;

ANIMALS; ANTIBODIES, MONOCLONAL; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL PRODUCTS; BLOOD-BRAIN BARRIER; BRAIN; CHO CELLS; CHROMATOGRAPHY, AFFINITY; CRICETINAE; CRICETULUS; DRUG STABILITY; IMMUNOGLOBULIN G; MACACA MULATTA; RECEPTOR, INSULIN; RECOMBINANT FUSION PROTEINS; REFRIGERATION; TIME FACTORS;

CRICETULUS GRISEUS; MACACA MULATTA; PRIMATES;

EID: 78649401642     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22907     Document Type: Article

References (29)

1. Bennett EL, Drori JB, Krech D, Rosenzweig MR, Abraham S. 1962. Hexokinase activity in brain. J Biol Chem 237: 1758-1763.
2. Bigl M, Bruckner MK, Arendt T, Bigl V, Eschrich K. 1999. Activities of key glycolytic enzymes in the brains of patients with Alzheimer's disease. J Neural Transm 106(5-6): 499-511.
3. Bird SB, Gaspari GJ, Dickson EW. 2003. Early death due to severe organophosphate poisoning is a centrally mediated process. Acad Emerg Med 10(4): 295-298.
4. Boado RJ, Zhang Y, Pardridge WM. 2007. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol Bioeng 97(6): 1376-1386.
5. Boado RJ, Zhang Y, Wang Y, Pardridge WM. 2008a. IgG-paraoxonase-1 fusion protein for targeted drug delivery across the human blood-brain barrier. Mol Pharm 5(6): 1037-1043.
6. Boado RJ, Zhang Y, Zhang Y, Xia CF, Wang Y, Pardridge WM. 2008b. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng 99(2): 475-484.
7. Boado RJ, Hui EK, Lu JZ, Pardridge WM. 2009a. AGT-181: Expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J Biotechnol 144(2): 135-141.
8. Boado RJ, Zhang Y, Wang Y, Pardridge WM. 2009b. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol Bioeng 102(4): 1251-1258.
9. Boado RJ, Pardridge WM. 2009. Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey. Drug Metab Dispos 37(12): 2299-2304.
10. Boado RJ, Hui EK, Lu JZ, Pardridge WM. 2010. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J Pharmacol Exp Ther 333(3): 961-969.
11. Choi EK, Park D, Yon JM, Hur GH, Ha YC, Che JH, Kim J, Shin S, Jang JY, Hwang SY, Seong YH, Kim DJ, Kim JC, Kim YB. 2004. Protection by sustained release of physostigmine and procyclidine of soman poisoning in rats. Eur J Pharmacol 505(1-3): 83-91.
12. Coloma MJ, Lee HJ, Kurihara A, Landaw EM, Boado RJ, Morrison SL, Pardridge WM. 2000. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res 17(3): 266-274.
13. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10(7): 1093-1095.
14. Deakin S, Leviev I, Gomaraschi M, Calabresi L, Franceschini G, James RW. 2002. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem 277(6): 4301-4308.
15. Draganov DI, La Du BN. 2004. Pharmacogenetics of paraoxonases: A brief review. Naunyn Schmiedebergs Arch Pharmacol 369(1): 78-88.
16. Gaidukov L, Tawfik DS. 2005. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 44(35): 11843-11854.
17. Gillis RA, Walton DP, Quest JA, Namath IJ, Hamosh P, Dretchen KL. 1988. Cardiorespiratory effects produced by activation of cholinergic muscarinic receptors on the ventral surface of the medulla. J Pharmacol Exp Ther 247(2): 765-773.
18. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, Dvir H, Ravelli RB, McCarthy A, Toker L, Silman I, Sussman JL, Tawfik DS. 2004. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 11(5): 412-419.
19. Kujiraoka T, Oka T, Ishihara M, Egashira T, Fujioka T, Saito E, Saito S, Miller NE, Hattori H. 2000. A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration. J Lipid Res 41(8): 1358-1363.
20. Lenz DE, Yeung D, Smith JR, Sweeney RE, Lumley LA, Cerasoli DM. 2007. Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: A mini review. Toxicology 233(1-3): 31-39.
21. Oldendorf WH, Pardridge WM, Braun LD, Crane PD. 1982. Measurement of cerebral glucose utilization using washout after carotid injection in the rat. J Neurochem 38: 1413-1418.
22. Pardridge WM, Boado RJ. 2009. Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery. Pharm Res 26(10): 2227-2236.
23. Pardridge WM, Kang YS, Buciak JL, Yang J. 1995. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res 12(6): 807-816.
24. Pardridge WM. 2010. Biopharmaceutical drug targeting to the brain. J Drug Target 18(3): 157-167.
25. Rochu D, Chabriere E, Masson P. 2007. Human paraoxonase: A promising approach for pre-treatment and therapy of organophosphorus poisoning. Toxicology 233(1-3): 47-59.
26. Soukharev S, Hammond DJ. 2004. A fluorogenic substrate for detection of organophosphatase activity. Anal Biochem 327(1): 140-148.
27. Tougou K, Nakamura A, Watanabe S, Okuyama Y, Morino A. 1998. Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab Dispos 26(4): 355-359.
28. Yeung DT, Josse D, Nicholson JD, Khanal A, McAndrew CW, Bahnson BJ, Lenz DE, Cerasoli DM. 2004. Structure/function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase-like homology model. Biochim Biophys Acta 1702(1): 67-77.
29. Zhou QH, Boado RJ, Lu JZ, Hui EK, Pardridge WM. 2010. Monoclonal antibody-glial cell derived neurotrophic factor fusion protein penetrates the blood brain barrier in the mouse. Drug Metab Dispos 38(4): 566-572.